Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Central Nervous System Neoplasms 3Fatigue 2Breast Neoplasms 2Brain Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Radiation Injuries 1Ototoxicity 1Melanoma 1Gliosarcoma 1Glioblastoma 1Depression 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1

Interventions

Temozolomide 27Radiotherapy 21Radiation 11Radiotherapy, Conformal 10Surgical Procedures, Operative 9Magnetic Resonance Spectroscopy 8Carmustine 8Radiotherapy, Intensity-Modulated 7Erlotinib Hydrochloride 7temsirolimus 6Vorinostat 6Sirolimus 6Chemotherapy, Adjuvant 6Bevacizumab 6motexafin gadolinium 5cediranib 5Cilengitide 5Carboplatin 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5tipifarnib 4Sorafenib 4Immunoglobulin G 4Disulfides 4Congresses as Topic 4Procarbazine 3O(6)-benzylguanine 3Nivolumab 3Neoadjuvant Therapy 3Lapatinib 3Ipilimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Gliosarcoma × Mental Status and Dementia Tests × Clear all
NCT00731731 2022-08-04

Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 1/2 Completed
125 enrolled 12 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡